A procedure that can take days can be reduced to around an hour through a new method that harvests stem cells for bone marrow donors and cancer patients.
For bone marrow transplantation, stem cells are routinely harvested from healthy donors and used to treat patients with cancers including leukaemia. Current harvesting methods take a long time and require injections of a growth factor to boost stem cell numbers. This often leads to side effects.
Our technology can reduce time and cost associated with current methods.
- Our researchers have developed a method that combines a molecule (known as BOP), with an existing type of molecule (AMD3100) to mobilise the stem cells found in bone marrow out into the blood stream.
- The BOP small molecule improves HSCT by being a single injection and working within a few hours, drastically reducing expense and inconvenience for patients.
- In the early stage of planning clinical trials.
- HSCT market is significant – there are approximately 100k procedures a year at a cost of up to $50k
- Key markets are myeloma and leukemia – both auto and allogeneic transplantation
- BOP may also treat other cancers in conjunction with other drugs.
Patents published June 2016 in relation to mobilising stem cells from the bone marrow.
Our team boasts over 25 years' experience in their field with expertise in haematology research, bone marrow stem cell research, cancer biology and organic chemistry. We have significant expertise working with mouse models for mobilisation and leukemic xenograft models for chemosensitisation.